Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

CorMedix (CRMD) EBT: 2012-2025

Historic EBT for CorMedix (CRMD) over the last 12 years, with Sep 2025 value amounting to $52.6 million.

  • CorMedix's EBT rose 1993.40% to $52.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $107.0 million, marking a year-over-year increase of 351.65%. This contributed to the annual value of -$19.3 million for FY2024, which is 58.30% up from last year.
  • Latest data reveals that CorMedix reported EBT of $52.6 million as of Q3 2025, which was up 158.37% from $20.3 million recorded in Q2 2025.
  • Over the past 5 years, CorMedix's EBT peaked at $52.6 million during Q3 2025, and registered a low of -$15.9 million during Q1 2024.
  • In the last 3 years, CorMedix's EBT had a median value of -$6.3 million in 2023 and averaged $4.3 million.
  • As far as peak fluctuations go, CorMedix's EBT slumped by 60.27% in 2023, and later spiked by 1,993.40% in 2025.
  • Quarterly analysis of 5 years shows CorMedix's EBT stood at -$7.8 million in 2021, then fell by 5.36% to -$8.2 million in 2022, then crashed by 42.18% to -$9.7 million in 2023, then spiked by 71.50% to $13.5 million in 2024, then surged by 1,993.40% to $52.6 million in 2025.
  • Its EBT stands at $52.6 million for Q3 2025, versus $20.3 million for Q2 2025 and $20.6 million for Q1 2025.